Suzhou Dejin Biopharmaceutical Co., Ltd.

The primary objective of Phase I is to evaluate the safety and tolerability of DJ-01 injection in improving moderate to severe glabellar lines. The secondary objectives of Phase I are to evaluate the preliminary effectiveness of DJ-01 injection in improving moderate to severe glabellar lines; and to evaluate the immunogenicity of DJ-01 injection in improving moderate to severe glabellar lines. The primary objective of Phase II is to evaluate the effectiveness of DJ-01 injection in improving moderate to severe glabellar lines; the secondary objectives of Phase II are to evaluate the other effectiveness of DJ-01 injection in improving moderate to severe glabellar lines; and to evaluate the safety of DJ-01 injection in improving moderate to severe glabellar lines; and to evaluate the immunogenicity of DJ-01 injection in improving moderate to severe glabellar lines.